Second-line rituximab, lenalidomide, and bendamustine (R2B) in mantle cell lymphoma: a phase 2 clinical trial of the Fondazione Italiana Linfomi

Francesco Zaja, Simone Ferrero, Caterina Stelitano, Angela Ferrari, Flavia Salvi, Annalisa Arcari, Gerardo Musuraca, Barbara Botto, Michele Spina, Claudia Cellini, Caterina Patti, Anna M. Liberati, Claudia Minotto, Stefano A. Pileri, Manuela Ceccarelli, Stefano Volpetti, Antonella Ferranti, Daniela Drandi, Elisa Montechiarello, Marco Ladetto, James Carmichael, and Renato Fanin

Disclosures: J.C. is employed by Celgene. J.C. owns stock of Celgene. R.F. received honoraria from Celgene, Roche and Mundipharma; M.L. has received honoraria from Amgen, Celgene, Gilead, Mundipharma, Novartis, J&J, Roche, Roche Diagnostics, Spectum and Takeda; S.V. received honoraria from Teva Italy; F.Z. received honoraria from Celgene, Roche and Mundipharma. R.F. has consulting or advisory roles with Celgene and Roche; M.L. has consulting or advisory roles with Amgen, Celgene, Gilead, Mundipharma, Novartis, J&J, Roche, Roche Diagnostics, Spectum and Takeda; F.Z. has a consulting or advisory role with Celgene and Roche. S.P. has a consulting or advisory role with Takeda/Millennium. R.F. receives research funding from Celgene and Roche; S.F. receives research funding from Amgen, Celgene, Gilead, Mundipharma, Novartis, J&J, Roche, Roche Diagnostics, Spectum and Takeda; F.Z. receives research funding from Celgene and Roche. S.F. has served on speakers bureaux for Mundipharma, Celgene, Pfizer and Janssen; M.L. has served on speakers bureaux for Amgen, Celgene, Gilead, Mundipharma, Novartis, J&J, Roche, Roche Diagnostics, Spectum and Takeda. R.F. has received travel, accommodation or expenses from Celgene, Roche and Mundipharma; S.F. has received travel, accommodation or expenses from Mundipharma, Spectrum and Janssen; J.C. has received travel, accommodation or expenses from Celgene; S.V. has received travel, accommodation or expenses from Roche; F.Z. has received travel, accommodation or expenses from Celgene, Roche and Mundipharma. A.A., B.B., C.C., C.M., D.D., A. Ferranti, A. Ferrari, A.M.L., C.M., G.M., C.P., S.P., F.S., M.S., C.S., declare no competing financial interests.